Paul Chapman, MD — Professor of Medicine — Scholars @ Weill Cornell Medicine

ScholarsBetaWeill Cornell Medicine

Highlights

1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
ANAlexander Noor Shoushtari JDJedd D Wolchok MAMichael Andrew Postow PCPaul Chapman
PMID: 32053428PMCID: PMC7238490DOISenior author181 citations
2
European journal of cancer (Oxford, England : 1990) · 2020
PCPaul Chapman
PMID: 31864178PMCID: PMC8073226DOISenior author65 citations
3
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
JDJedd D Wolchok PCPaul Chapman
PMID: 34928709PMCID: PMC8966970DOISenior author48 citations

Publications

210

Funding

3 View NIH portfolio on RePORTER ↗

Completed grants (3)

PI
Phase II trial of 17-AAG in melanoma patients
NCI · 2006–2009 · via NIH RePORTER
R21CA112899-02
PI
Anti-GD3 NKT cells as effector cells against melanoma
NCI · 2003–2008 · via NIH RePORTER
R01CA097041-04
PI
IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
NCI · 1999–2005 · via NIH RePORTER
K24CA081293-05

Clinical research

1

Active

1 study

PI
A Pilot Trial of Bright Light Therapy in Patients Receiving First Line Immune Checkpoint Blockade
NA · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
Melanoma (Skin Cancer); NSCLC (Non-small Cell Lung Cancer)
NCT07661966

Media highlights

3

Intratumoral Immunotherapy Draws Renewed Attention But Does It Work?
Medscape · October 16, 2026
What Happened At FDA? Replimune Approval Raises Questions
The Cancer Letter · August 13, 2026
FDA Expert Committee Votes In Favor Of Replimune’s Melanoma Treatment
STAT · August 3, 2026

Mentoring

2 All publications with mentees →

External relationships

Ownership

Rgenix, Inc.

Other

Immunocore Limited